ReviewMolecular bioSystems2010
Allosteric activators of muscarinic receptors as novel approaches for treatment of CNS disorders.
Review in Molecular bioSystems, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- A golden age of muscarinic acetylcholine receptor modulation in neurological diseases.Nature reviews. Drug discovery · 2024Review
- Analysing the effect caused by increasing the molecular volume in M1-AChR receptor agonists and antagonists: a structural and computational study.RSC advances · 2024Article
- Article
- Pathophysiology and pharmacology of G protein-coupled receptors in the heart.Cardiovascular research · 2023Review
- Muscarinic Acetylcholine Receptors in the Retina-Therapeutic Implications.International journal of molecular sciences · 2021Review
- An allosteric modulator binds to a conformational hub in the βNature chemical biology · 2020Article
- G Protein-Coupled Receptors in Asthma Therapy: Pharmacology and Drug Action.Pharmacological reviews · 2020Review
- Cryptic pocket formation underlies allosteric modulator selectivity at muscarinic GPCRs.Nature communications · 2019Article
- Cholinergic modulation of striatal microcircuits.The European journal of neuroscience · 2019Review
- Muscarinic agonist, (±)-quinuclidin-3-yl-(4-fluorophenethyl)(phenyl)carbamate: High affinity, but low subtype selectivity for human MBioorganic & medicinal chemistry letters · 2019Article
- Crystal structure of the human angiotensin II type 2 receptor bound to an angiotensin II analog.Nature structural & molecular biology · 2018Article
- Positive allosteric modulation of MNeuropharmacology · 2018Review
- Drugs Interfering with Muscarinic Acetylcholine Receptors and Their Effects on Place Navigation.Frontiers in psychiatry · 2017Review
- Further optimization of the M1 PAM VU0453595: Discovery of novel heterobicyclic core motifs with improved CNS penetration.Bioorganic & medicinal chemistry letters · 2016Article
- An Antibody Biosensor Establishes the Activation of the M1 Muscarinic Acetylcholine Receptor during Learning and Memory.The Journal of biological chemistry · 2016Article
- Article
- Cholinergic interneurons in the dorsal and ventral striatum: anatomical and functional considerations in normal and diseased conditions.Annals of the New York Academy of Sciences · 2015Review
- Novel insights into M3 muscarinic acetylcholine receptor physiology and structure.Journal of molecular neuroscience : MN · 2014Review
- Muscarinic acetylcholine receptor X-ray structures: potential implications for drug development.Current opinion in pharmacology · 2014Review
- Employing novel animal models in the design of clinically efficacious GPCR ligands.Current opinion in cell biology · 2014Review
Corrections and comments
- Erratum issued
Authors and funding
3 authors.
Funding
Abstract
Muscarinic acetylcholine receptors (mAChRs) represent exciting therapeutic targets for the treatment of multiple CNS disorders. The high degree of conservation of amino acids comprising the orthosteric acetylcholine (ACh) binding site between individual mAChR subtypes has hindered the development of subtype-selective compounds that bind to this site. As a result, many academic and industry researchers are now focusing on developing allosteric activators of mAChRs including both positive allosteric modulators (PAMs) and allosteric agonists. In the past 10 years major advances have been achieved in the discovery of allosteric ligands that possess much greater selectivity for individual mAChR subtypes when compared to previously developed orthosteric agents. These novel allosteric modulators of mAChRs may provide therapeutic potential for treatment of a number of CNS disorders such as Alzheimer's disease and schizophrenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.